Aducanumab Binding to Aβ1-42 Fibrils Alters Dynamics of the N-Terminal Tail While Preserving the Fibril Core https://www.biorxiv.org/content/10.1101/2025.11.01.686027v1
November 3, 2025 at 11:47 PM
Aducanumab Binding to Aβ1-42 Fibrils Alters Dynamics of the N-Terminal Tail While Preserving the Fibril Core https://www.biorxiv.org/content/10.1101/2025.11.01.686027v1
Aducanumab Binding to Aβ1-42 Fibrils Alters Dynamics of the N-Terminal Tail While Preserving the Fibril Core https://www.biorxiv.org/content/10.1101/2025.11.01.686027v1
November 3, 2025 at 11:47 PM
Aducanumab Binding to Aβ1-42 Fibrils Alters Dynamics of the N-Terminal Tail While Preserving the Fibril Core https://www.biorxiv.org/content/10.1101/2025.11.01.686027v1
#MedNews - Treatment with the anti-amyloid-β antibody #aducanumab clears amyloid from superficial cortical layers more than in deeper tissue.
Full story 👉 buff.ly/XLteVb3
#NeuroSky #Alzheimers
Full story 👉 buff.ly/XLteVb3
#NeuroSky #Alzheimers
Aducanumab amyloid-β-clearing strongest in superficial cortex
Treatment with the anti-amyloid-β antibody aducanumab clears amyloid from superficial cortical layers more than in deeper tissue.
www.springermedicine.com
October 28, 2025 at 11:54 AM
#MedNews - Treatment with the anti-amyloid-β antibody #aducanumab clears amyloid from superficial cortical layers more than in deeper tissue.
Full story 👉 buff.ly/XLteVb3
#NeuroSky #Alzheimers
Full story 👉 buff.ly/XLteVb3
#NeuroSky #Alzheimers
🚨New in Lancet Neurology: Autopsy study of aducanumab in #Alzheimer’s shows superficial cortical Aβ cleared, but deeper persists. ARIA showed inflammation+ microinfarcts in leptomeningeal/penetrating vessels. Some path is PET-invisible. @drneurochic.bsky.social
authors.elsevier.com/a/1lxn85FFzL...
authors.elsevier.com/a/1lxn85FFzL...
October 16, 2025 at 10:33 AM
🚨New in Lancet Neurology: Autopsy study of aducanumab in #Alzheimer’s shows superficial cortical Aβ cleared, but deeper persists. ARIA showed inflammation+ microinfarcts in leptomeningeal/penetrating vessels. Some path is PET-invisible. @drneurochic.bsky.social
authors.elsevier.com/a/1lxn85FFzL...
authors.elsevier.com/a/1lxn85FFzL...
RFK, Jr. was right all along!! He just got the words wrong when he confused autism with Alzeheimer's.
The false God of science. All Gods are false.
"Some physicians believe aducanumab never should have been approved, while others maintain it should be given a chance."
The false God of science. All Gods are false.
"Some physicians believe aducanumab never should have been approved, while others maintain it should be given a chance."
Alzheimer's May Not Actually Be a Brain Disease, Reveals Expert
The pursuit of a cure for Alzheimer's disease is becoming an increasingly competitive and contentious quest, with recent years witnessing several important controversies.
www.sciencealert.com
October 12, 2025 at 6:25 PM
RFK, Jr. was right all along!! He just got the words wrong when he confused autism with Alzeheimer's.
The false God of science. All Gods are false.
"Some physicians believe aducanumab never should have been approved, while others maintain it should be given a chance."
The false God of science. All Gods are false.
"Some physicians believe aducanumab never should have been approved, while others maintain it should be given a chance."
---
*thoughts about Alexander Ross – Aducanumab Chair*
The synths creak like fluorescent hospital lights, sterile and buzzing, setting a clinical hush around the oddball title. Bass moves in slow, anesthetic swells, a careful drip that keeps the room suspended between focus and drift. Percuss...
*thoughts about Alexander Ross – Aducanumab Chair*
The synths creak like fluorescent hospital lights, sterile and buzzing, setting a clinical hush around the oddball title. Bass moves in slow, anesthetic swells, a careful drip that keeps the room suspended between focus and drift. Percuss...
October 4, 2025 at 11:06 PM
---
*thoughts about Alexander Ross – Aducanumab Chair*
The synths creak like fluorescent hospital lights, sterile and buzzing, setting a clinical hush around the oddball title. Bass moves in slow, anesthetic swells, a careful drip that keeps the room suspended between focus and drift. Percuss...
*thoughts about Alexander Ross – Aducanumab Chair*
The synths creak like fluorescent hospital lights, sterile and buzzing, setting a clinical hush around the oddball title. Bass moves in slow, anesthetic swells, a careful drip that keeps the room suspended between focus and drift. Percuss...
---
*thoughts about Alexander Ross – Aducanumab Chair*
The synths hum like fluorescent lights in a sterile boardroom, and the melody leans back with a clinical smirk while the title jabs at biotech hubris without raising its voice. It’s cool, precise, and a little poisonous—like a patent fili...
*thoughts about Alexander Ross – Aducanumab Chair*
The synths hum like fluorescent lights in a sterile boardroom, and the melody leans back with a clinical smirk while the title jabs at biotech hubris without raising its voice. It’s cool, precise, and a little poisonous—like a patent fili...
September 28, 2025 at 8:05 PM
---
*thoughts about Alexander Ross – Aducanumab Chair*
The synths hum like fluorescent lights in a sterile boardroom, and the melody leans back with a clinical smirk while the title jabs at biotech hubris without raising its voice. It’s cool, precise, and a little poisonous—like a patent fili...
*thoughts about Alexander Ross – Aducanumab Chair*
The synths hum like fluorescent lights in a sterile boardroom, and the melody leans back with a clinical smirk while the title jabs at biotech hubris without raising its voice. It’s cool, precise, and a little poisonous—like a patent fili...
The “promised cures have fizzled” is a link to an article about the biologic therapeutic aducanumab, which targets beta-amyloid “plaques” in Alzheimer's patients. The main problem there is a still insufficient basic scientific understanding of the mechanism behind neurodegenerative etiologies
/3c
/3c
September 22, 2025 at 2:56 PM
The “promised cures have fizzled” is a link to an article about the biologic therapeutic aducanumab, which targets beta-amyloid “plaques” in Alzheimer's patients. The main problem there is a still insufficient basic scientific understanding of the mechanism behind neurodegenerative etiologies
/3c
/3c
Pequeños ensayos del uso de litio en pacientes con Alzheimer muestran que el litio puede ralentizar el deterioro cognitivo +podría ser más efectivo y seguro que aducanumab, y al menos tan efectivo como donanemab y lecanemab
Tiembla industria farmaceutica
elpais.com/ciencia/mate...
Tiembla industria farmaceutica
elpais.com/ciencia/mate...
Enfermedad de alzhéimer: el litio da esperanza
Una investigación publicada en ‘Nature’ ha puesto de manifiesto, una vez más, las posibilidades terapéuticas de este metal alcalino
elpais.com
September 12, 2025 at 9:01 AM
Pequeños ensayos del uso de litio en pacientes con Alzheimer muestran que el litio puede ralentizar el deterioro cognitivo +podría ser más efectivo y seguro que aducanumab, y al menos tan efectivo como donanemab y lecanemab
Tiembla industria farmaceutica
elpais.com/ciencia/mate...
Tiembla industria farmaceutica
elpais.com/ciencia/mate...
Dementia experts are optimistic about fresh treatments since the development of Aducanumab but do not want to raise false hopes of a possible cure
New Alzheimer’s drugs are coming. How excited should we be?
Dementia experts are optimistic about fresh treatments since the development of Aducanumab but do not want to raise false hopes of a possible cure
www.thetimes.com
August 22, 2025 at 3:32 PM
Dementia experts are optimistic about fresh treatments since the development of Aducanumab but do not want to raise false hopes of a possible cure
I used to work for a company who developed & marketed 2 drugs for Alzheimer’s (aducanumab & lecanemab). The first product was discontinued (lack of commercial success). Lecanemab is showing results in slowing the disease progression but sadly it’s about price & whether the NHS is willing to pay.
August 22, 2025 at 9:21 AM
I used to work for a company who developed & marketed 2 drugs for Alzheimer’s (aducanumab & lecanemab). The first product was discontinued (lack of commercial success). Lecanemab is showing results in slowing the disease progression but sadly it’s about price & whether the NHS is willing to pay.
5/10
Efectos adversos
Alzheimer. Medicamentos inútiles y peligrosos. Muerte
Warning about Amyloid-lowering antibodies for Alzheimer's disease. Serious Harm. Lecanemab. Aducanumab. Death and Refractory Status Epilepticus
pubmed.ncbi.nlm.nih.gov/39121445/
www.alzforum.org/news/confere...
Efectos adversos
Alzheimer. Medicamentos inútiles y peligrosos. Muerte
Warning about Amyloid-lowering antibodies for Alzheimer's disease. Serious Harm. Lecanemab. Aducanumab. Death and Refractory Status Epilepticus
pubmed.ncbi.nlm.nih.gov/39121445/
www.alzforum.org/news/confere...
July 28, 2025 at 8:41 AM
5/10
Efectos adversos
Alzheimer. Medicamentos inútiles y peligrosos. Muerte
Warning about Amyloid-lowering antibodies for Alzheimer's disease. Serious Harm. Lecanemab. Aducanumab. Death and Refractory Status Epilepticus
pubmed.ncbi.nlm.nih.gov/39121445/
www.alzforum.org/news/confere...
Efectos adversos
Alzheimer. Medicamentos inútiles y peligrosos. Muerte
Warning about Amyloid-lowering antibodies for Alzheimer's disease. Serious Harm. Lecanemab. Aducanumab. Death and Refractory Status Epilepticus
pubmed.ncbi.nlm.nih.gov/39121445/
www.alzforum.org/news/confere...
Full article: Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab #mAbs www.tandfonline.com/doi/full/10....
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab
A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyl...
www.tandfonline.com
July 24, 2025 at 3:43 AM
Full article: Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab #mAbs www.tandfonline.com/doi/full/10....
such as #aducanumab for #Alzheimerdisease, #tofersen for ALS , #delandistrogene #moxeparvovec for #Duchennemusculardystrophy & #voxelotor for #sicklecelldisease
@jama.com
ja.ma/3GHGhDE
jamanetwork.com/journals/jam...
@jama.com
ja.ma/3GHGhDE
jamanetwork.com/journals/jam...
Regulatory and Clinical Outcomes of Nononcology Accelerated Approvals
This study uses US Food and Drug Administration (FDA) data to characterize pivotal and confirmatory trials supporting agency decision-making in the context of the FDA accelerated approval pathway for ...
jamanetwork.com
July 14, 2025 at 4:03 PM
📃Scientific paper: TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
June 18, 2025 at 4:00 AM
📃Scientific paper: TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
Wasn't the FDA already doing this? re: aducanumab and andexanet Alfa accelerated approval. Neither ended well, and everyone knew it was going to end badly from the moment of approval
June 6, 2025 at 12:12 AM
Wasn't the FDA already doing this? re: aducanumab and andexanet Alfa accelerated approval. Neither ended well, and everyone knew it was going to end badly from the moment of approval
Accelerated approval of neurology drugs is under scrutiny such as controversial FDA approvals of aducanumab (Aduhelm) and eteplirsen (Exondys 51). Do you favor accelerated approval or a strict requirement of class Ia evidence? journals.lww.com/neurotodayon...
FDA Accelerated Approvals Are Under Scrutiny: Neurology... : Neurology Today
An abstract is unavailable.
journals.lww.com
May 30, 2025 at 12:21 AM
Accelerated approval of neurology drugs is under scrutiny such as controversial FDA approvals of aducanumab (Aduhelm) and eteplirsen (Exondys 51). Do you favor accelerated approval or a strict requirement of class Ia evidence? journals.lww.com/neurotodayon...
📃Scientific paper: TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
May 28, 2025 at 4:00 AM
📃Scientific paper: TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
Aducanumab delivery via focused ultrasound-induced transient blood-brain barrier opening in vivo.
https://pubmed.ncbi.nlm.nih.gov/40404732/
#neurodegeneration #ASO
https://pubmed.ncbi.nlm.nih.gov/40404732/
#neurodegeneration #ASO
May 23, 2025 at 3:23 PM
Aducanumab delivery via focused ultrasound-induced transient blood-brain barrier opening in vivo.
https://pubmed.ncbi.nlm.nih.gov/40404732/
#neurodegeneration #ASO
https://pubmed.ncbi.nlm.nih.gov/40404732/
#neurodegeneration #ASO
We studied the binding of clinical antibodies to human brain extracts and found no evidence that lecanemab binds a more soluble population of Abeta than aducanumab or donanemab, nor that binding preferences to CAA vs plaque explained different ARIA rates. www.biorxiv.org/content/10.1...
Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain
Importance: Anti-amyloid immunotherapy is used to treat Alzheimer disease (AD) with moderate benefits and potentially serious side effects due to amyloid related imaging abnormality with effusions/ede...
www.biorxiv.org
May 21, 2025 at 11:27 PM
We studied the binding of clinical antibodies to human brain extracts and found no evidence that lecanemab binds a more soluble population of Abeta than aducanumab or donanemab, nor that binding preferences to CAA vs plaque explained different ARIA rates. www.biorxiv.org/content/10.1...
TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease
INTRODUCTION The phase 3, open-label TRAILBLAZER-ALZ 4 study compared the effect of donanemab versus aducanumab on amyloid plaque (AP) clearance in participants with early symptomatic Alzheimer's di...
alz-journals.onlinelibrary.wiley.com
May 20, 2025 at 12:43 PM
TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Like #Prasad, I had also strongly disagreed with way #eteplirsen and #aducanumab were approved. It is not about being all or nothing, but nuance.
May 7, 2025 at 2:13 PM
Like #Prasad, I had also strongly disagreed with way #eteplirsen and #aducanumab were approved. It is not about being all or nothing, but nuance.
📃Scientific paper: TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
April 20, 2025 at 4:00 AM
📃Scientific paper: TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
Ref.: Cambridge University Press, 2023
➡️ Continued on ES/IODE
A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases www.frontiersin.org/journals/pha...
Frontiers | A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases
www.frontiersin.org
April 2, 2025 at 5:50 AM
A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases www.frontiersin.org/journals/pha...